European PCV2 Research Award Goes to Werling
EU - Infections with Porcine Circovirus Type 2 (PCV2) have caused economical losses to the pig industry in the past, mostly by affecting growing and fattening pigs. Now, as very effective piglet vaccines are available, clinical disease in pigs is seldom observed.
25 March 2014
2 minute read
Still many questions related to PCV2 remain unanswered. Among others: Is it possible to eradicate PCV2? Does PCV2 vaccination influence viral evolution? What is the impact of PCV2 on sows? Where does the virus initially replicate?
The European Porcine Circovirus (PCV2) Research Award is an annual award sponsored by Boehringer Ingelheim that recognizes research proposals in the area of applied immunological PCV2 research.
The award has an independent review board with leading European scientists in applied porcine research reviewing the entries and deciding upon the winning proposals.
This year, eleven high quality research proposals were submitted from different countries (UK, Italy, Spain, Sweden, Denmark, Estonia, and France, Germany).
Three awards, each with a value of €25,000 were made, one of which was awarded to Professor Dirk Werling of the Royal Veterinary College in the UK.
